October 10, 2024 03:49 PM EDT
R&D
FDA+

Sev­en pa­tients di­ag­nosed with blood can­cer af­ter Skysona treat­ment, new da­ta show

Nicole DeFeudis

Editor

Sev­en young boys treat­ed with blue­bird bio’s gene ther­a­py for a rare neu­ro­log­i­cal dis­ease have been di­ag­nosed with blood can­cer months or years af­ter treat­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

FDA ap­proves Roche's new treat­ment for sub­set of breast can­cer pa­tients

Ex­clu­sive: How an ac­ci­den­tal email tipped Pfiz­er off to an ac­tivist in­vestor’s plan

Eli Lil­ly inks an­oth­er obe­si­ty pact, dou­bling down on small Swiss part­ner

Star­board launch­es first sal­vo in Pfiz­er fight, al­leg­ing ex-CEO, CFO were pres­sured to flip

Grit­stone files for bank­rupt­cy, says it could forge a trans­ac­tion as ear­ly as this month to keep R&D go­ing

Im­mat­ics heads to Phase 3 with melanoma cell ther­a­py, seeks to raise $150M

A service from the Financial Times